Mast Therapeutics initiates Phase 3 extension study of vepoloxamer in sickle cell disease
26 May 2015 | By Victoria White
Mast Therapeutics has initiated an open-label, multicentre Phase 3 extension study of vepoloxamer (MST-188) in sickle cell disease, referred to as "EPIC-E"...